Anton Kraxner

422 total citations
9 papers, 309 citations indexed

About

Anton Kraxner is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Anton Kraxner has authored 9 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Molecular Biology. Recurrent topics in Anton Kraxner's work include Peptidase Inhibition and Analysis (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Anton Kraxner is often cited by papers focused on Peptidase Inhibition and Analysis (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Anton Kraxner collaborates with scholars based in Switzerland, United States and France. Anton Kraxner's co-authors include Marion Sourisseau, Fernando Arenzana‐Seisdedos, Stephen Higgs, Marco Colonna, Nicolas Gangneux, Lucie Peduto, Fabrice Chrétien, Marc Lecuit, Florence Guivel‐Benhassine and Jürg Tschopp and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Anton Kraxner

9 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anton Kraxner Switzerland	5	210	195	91	55	37	9	309
Jan H. ter Meulen United States	7	155 0.7×	133 0.7×	158 1.7×	97 1.8×	78 2.1×	9	369
Annegret Bitzer Germany	7	150 0.7×	133 0.7×	80 0.9×	41 0.7×	128 3.5×	8	342
Karla M. Viramontes United States	12	243 1.2×	211 1.1×	97 1.1×	57 1.0×	54 1.5×	17	410
Jamie Saunders United Kingdom	5	154 0.7×	176 0.9×	27 0.3×	23 0.4×	23 0.6×	8	241
Natalie Lorenz New Zealand	12	125 0.6×	153 0.8×	110 1.2×	30 0.5×	101 2.7×	24	351
Cecília B. Cavazzoni United States	10	97 0.5×	127 0.7×	271 3.0×	31 0.6×	61 1.6×	18	441
Ann Ly United States	8	179 0.9×	49 0.3×	226 2.5×	22 0.4×	41 1.1×	14	345
Tânia Mara Pinto Dabés Guimarães Brazil	10	84 0.4×	99 0.5×	123 1.4×	19 0.3×	50 1.4×	25	312
Babacar Mbengué Senegal	11	162 0.8×	29 0.1×	97 1.1×	23 0.4×	54 1.5×	42	280
Sheena Monahan United States	5	94 0.4×	192 1.0×	125 1.4×	40 0.7×	60 1.6×	6	365

Countries citing papers authored by Anton Kraxner

Since Specialization

Citations

This map shows the geographic impact of Anton Kraxner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anton Kraxner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anton Kraxner more than expected).

Fields of papers citing papers by Anton Kraxner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anton Kraxner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anton Kraxner. The network helps show where Anton Kraxner may publish in the future.

Co-authorship network of co-authors of Anton Kraxner

This figure shows the co-authorship network connecting the top 25 collaborators of Anton Kraxner. A scholar is included among the top collaborators of Anton Kraxner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anton Kraxner. Anton Kraxner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Dejardin, David, et al.. (2024). An overview of statistical methods for biomarkers relevant to early clinical development of cancer immunotherapies. Frontiers in Immunology. 15. 1351584–1351584. 1 indexed citations

Kraxner, Anton, Wei‐Yi Cheng, Tai-Hsien Ou Yang, et al.. (2024). Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy. Frontiers in Immunology. 15. 1352632–1352632. 8 indexed citations

Dziadek, Sebastian, Anton Kraxner, Wei‐Yi Cheng, et al.. (2024). Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies. Frontiers in Immunology. 15. 1352615–1352615. 15 indexed citations

Dejardin, David, Anton Kraxner, Annika Blank, et al.. (2023). A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials. Clinical Cancer Research. 30(4). 877–882. 4 indexed citations

Hansen, Aaron R., Carlos Gomez‐Roca, Martijn P. Lolkema, et al.. (2021). 906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 32. S805–S805. 3 indexed citations

Dziadek, Sebastian, Anton Kraxner, Wei‐Yi Cheng, et al.. (2021). 86 Extensive FAP expression analysis in 23 tumor indications and potential application in defining the patient population in FAP-targeting cancer immunotherapies. Regular and Young Investigator Award Abstracts. A94–A94. 1 indexed citations

Italiano, Antoîne, Loïc Verlingue, Hans Prenen, et al.. (2021). Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.. Journal of Clinical Oncology. 39(15_suppl). 5510–5510. 19 indexed citations

Perez‐Gracia, José Luis, Aaron R. Hansen, Carlos Gomez‐Roca, et al.. (2021). Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).. Journal of Clinical Oncology. 39(15_suppl). 4556–4556. 7 indexed citations

Schilte, Clémentine, Thérèse Couderc, Fabrice Chrétien, et al.. (2010). Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. The Journal of Experimental Medicine. 207(2). 429–442. 251 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact